

## BioFacilities News / Updates

Tracking news/trends in the biologics industry; 100s of sources filtered by our analysts; 20+ years' experience. Your Source for Biologics industry news and trends.

---

### Inside this edition:

- Emergent BioSolutions investing USD \$75 MIL to develop viral vector gene therapies CMO manufacturing capacity in MA, USA
- Sanofi investing USD \$554 MIL to build a "state-of-the-art" vaccine manufacturing facility in France
- WuXi Biologics investing USD \$60 MIL in first U.S. CMO bioprocessing facility in MA, USA
- Lonza will use facilities in NH, USA, and Visp, Switzerland, to manufacture Covid-19 mRNA vaccine for Moderna

**Novo Nordisk**, through its foundation affiliate, is providing USD ~\$110 MIL in funding to Biosustain, a research center at the Technical University of Denmark (DTU), to develop and expand use of DTU's yeast 'cell factories' for manufacture of diverse biopharmaceutical and other products, with the goal of 'greener' manufacturing. *Source: Fierce Pharma, July 1, 2020*

**Cytiva (formerly GE)** expanded its Marlborough, Massachusetts, USA, including converting prior 'ballroom' manufacturing space into separate conventional suites. *Source: BioProcess Intl., June 24, 2020*

**Merck Animal Health (Merck & Co., Inc.)**, is investing USD \$100 MIL to expand veterinary vaccine manufacturing at its facility in DeSoto, Kansas, USA, and set aside another USD \$66 MIL for near-term future improvements. *Source: USNews.com, June 29, 2020*

**Emergent BioSolutions** is investing USD \$75 MIL to develop viral vector gene therapies CMO manufacturing capacity at its facility in Canton, Massachusetts, USA, operating at up to 1,000 L scale. *Source: Emergent BioSolutions press release, June 18, 2020*

**Sanofi** is investing USD \$554 MIL to build a "state-of-the-art" vaccine manufacturing facility, the Evolutive Vaccine Facility, at Neuville sur Saône, France, expected to be online in 5 years and employ 200 staff. *Source: FiercePharma, Jun 16, 2020*

**Grifols S.A. (Barcelona, Spain)** is investing USD \$352 MIL to expand its blood plasma products manufacturing facility in Clayton, North Carolina, USA. The facility also started production of Covid-19 immune globulin for treatment of Covid-19 in collaboration with BARDA. *Source: BioProcess Intl., June 15, 2020*

**Kite (Amsterdam, The Netherlands)**, a subsidiary of Gilead, received EU approval for manufacture of individualized cellular therapies, including its approved Yescarta therapy, with capacity for 4,000 cellular therapies/year. *Source: Gilead press release, June 12, 2020*

**WuXi Biologics** is building its first U.S. CMO bioprocessing facility in Worcester, Massachusetts, USA, investing USD \$60 MIL in a 107,000 sq. ft., ≥4,500 L capacity facility that will employ 150 staff. *Source: WuXi press release, June 11, 2020*

**Lonza (CMO)** will use facilities in Portsmouth, New Hampshire, USA, and Visp, Switzerland, to manufacture Covid-19 mRNA vaccine (mRNA-1273) for Moderna with plans to manufacture up to 1 BIL doses/year, with a 2nd ~\$70 MIL processing line coming online at the Visp facility. *Source: Reuters, June 2, 2020*

**Novavax (Gaithersburg, MD)** acquired Praha Vaccines (Czech Republic) for USD \$167 MIL and announced it will team up with Serum Institute of India for manufacture of ≥1 BIL doses/year of Covid-19 vaccine. The acquisition includes a facility in Bohumil, Czech Republic, now being fully retrofitted and updated. *Source: Pharma's Almanac, May 29, 2020*

**Avexis (Research Triangle Park, NC)**, a subsidiary of Novartis, will license and manufacture the Covid-19 gene therapy vaccine developed by Massachusetts General Hospital and Massachusetts Eye and Ear, USA. Avexis will manufacture the vaccine for free for use in clinical trials. *Source: WCG FDANews, May 29, 2020*

**Shanghai Henlius Biotech (Xuhui, China)** facility becomes the first bioprocessing facility in China to receive EU GMP certification for a China-developed biopharmaceutical, a biosimilar version of Herceptin, a mAb. *Source: GaBi, May 29, 2020*

**BARDA awarded AstraZeneca** a \$1.2 BIL contract from BARDA to support development and manufacture of 400 MIL doses of Covid-19 vaccine, shortly after concluding a deal with the UK government for purchase of 100 MIL doses. *Source: Genetic Eng. and Biotech. News (GEN), May 26, 2020*

**Vaxart hires Centaur Biopharmaceutical Services**, a CMO subsidiary of Kindred Biosciences (CMO, Burlingame, California, USA), to manufacture its oral Covid-19 vaccine. *Source: Covid-19 Industry Monitor, Contract Pharma, May 22, 2020*

**GlaxoSmithKline (GSK)** concluded an 8 year, USD \$231 MIL, contract with Samsung Biologics for commercial biopharmaceutical manufacturing, starting with Benlysta, a monoclonal antibody product. *Source: FiercePharma, May 22, 2020*

**U.K.'s Vaccines Manufacturing and Innovation Centre (VMIC)** received USD \$165 MIL government funding with a new facility expected to support UK pandemic vaccines manufacturing efforts, with VMIC partnering with vaccine developers worldwide for UK manufacture. *Source: FiercePharma, May 21, 2020*

**Exyte (Stuttgart, Germany) and Univercells Technologies (Gosselies, Belgium)** will partner to offer rapid construction of modular standardized and flexible GMP facilities for Covid-19 vaccine manufacture. *Source: Exyte and Univercells Technologies press release, May 14, 2020*

**Oxford Biomedica (Oxford, UK)** received UK GMP approval of its first 2 GMP gene therapies manufacturing suites and supporting labs. and other facilities, with 6 suites planned, 4 for viral vectors manufacturing. *Source: Oxford Biomedica press release, May 13, 2020*

**Pfizer** will shift existing manufacturing at multiple facilities to CMOs to make room for in-house manufacture of  $\geq 1$  BIL dose/year of Covid-19 vaccine, with its current CMOs, including Patheon/Thermo Fisher, Lonza and Catalent expected to receive additional work. *Source: Biopharma-Reporter.com, May 12, 2020*

**Pfizer** will use 3 of its facilities in the U.S. -- raw material manufacture at St. Louis, Missouri; vaccine API manufacture at Andover, Massachusetts; and fill-finish at Kalamazoo, Michigan - - and a facility in Puurs, Belgium, for manufacture of its Covid-19 vaccine (licensed from BioNTech) “at risk,” even before any trial results are available. BioNTech will also manufacture at its 2 facilities in Germany. Plans include manufacture of  $>1$  billion doses/year. *Source: FiercePharma, May 7, 2020*



Join colleagues at [The Waterside Conference](#), sponsored by **BioProcessing Journal**

**November 16-18, 2020, Newport Beach, CA, USA**

---

## Additional BioFacilities News

**Univercells Technologies (Gosselies, Belgium)**, a new subsidiary of Univercells, will provide cellular and gene therapy CMO services using its scale-X bioreactor and the NevoLine biomanufacturing platforms. *Source: Contract Pharma, May 5, 2020*

**BioCentriq (Newark, NJ)** will be the new cell and gene therapy production and manufacturing center for New Jersey Innovation Institute. It's claimed to be “the first of its kind to be located on a university campus in the United States,” besides offering one of the few cellular and gene therapy graduate degree programs in the U.S. *Source: BioCentriq press release, May 3, 2020*

**Lonza (CMO)** will manufacture Moderna's mRNA Covid-19 vaccine (licensed from Jenner Institute and Oxford Vaccine Group), mRNA-1273, at facilities in the U.S. and Switzerland, with plans for manufacture of up to 1 BIL doses/year. *Source: FiercePharma, May 1, 2020*

**Janssen Pharmaceuticals (Johnson & Johnson Co.)** will use Catalent's (CMO) facilities in Bloomington, Indiana, USA, to be the lead commercial fill-finish (lyophilization and pre-filled syringes) manufacturer of its Covid-19 vaccine, with 300 new staff to be hired. *Source: Pharma's Almanac, April 30, 2020*

**BioReliance, Merck KGaA (Germany)** is investing USD ~\$110 MIL to construct a new viral vector gene therapies 140,000 sq. ft. CMO facility in Carlsbad, California, USA, with this following a recently completed 65,000 sq. ft. expansion. The facility will operate at the 1,000 L scale. *Source: BioPharma Dive, April 23, 2020*

**Catalent (formerly Cook Pharmica)** completed construction of a 15,000 sq. ft., USD \$14 MIL expansion of its biologics fill-finish capabilities including handling "vials, syringes, and other devices with no glass-to-glass contact." *Source: Contract Pharma, April 23, 2020*

**Janssen Pharmaceuticals** will use Emergent BioSolutions's (CMO), Baltimore, Maryland, USA, facility for large-scale commercial manufacturing of Janssen's Covid-19 vaccine, with the goal of >1 BIL doses/year, following the signing of a 5-year contract. More capacity is being added at the facility. *Source: Emergent BioSolutions press release, April 23, 2020*

**New Age Industries** established a company-wide Priority Response Team to expedite orders from customers for Covid-19-related orders. Other vendors are also giving priority to pandemic-related orders. *Source: AdvantaPure Coronavirus Update, March 24, 2020*

**Thermo Fisher Scientific** is acquiring Qiagen (The Netherlands) for USD \$11.5 BIL. *Source: BioPharma Intl., March 5, 2020*

---

## BioPlan Publications



### NEW! AVAILABLE NOW!

The **2020 17th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production**, BioPlan's most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production, will soon be available. [Click here for Table of Contents](#)

---

**Questions? Comments? Let us know. Our interest is to provide you the highest value information and service available.**

**If you require custom research, BioPlan Associates, Inc., has been delivering actionable market data and customer analysis to the biopharma and life sciences industries for 30 years.**

**Contact us for a free evaluation and research proposal. [info@bioplanassociates.com](mailto:info@bioplanassociates.com)**

